Nestle near deal for Pfizer's baby formula unit - WSJ

Wed Apr 18, 2012 6:39am IST

Related Topics

Stocks

   

REUTERS - Pfizer Inc (PFE.N) is near a deal to sell its baby formula business to Swiss food giant Nestle SA (NESN.VX) for at least $9 billion, the Wall Street Journal reported on Tuesday.

Citing people familiar with the matter, the Journal said Nestle appears to have outstripped Danone and Mead Johnson Nutrition Co, who had teamed up for a bid, and that a deal could be announced as soon as next week.

Nestle, the world's biggest packaged food company, was already seen as a favored bidder due largely to its deep pockets.

Bloomberg reported that Danone and Nestle both submitted final offers of about $10 billion for the business, citing people with knowledge of the matter.

According to that report, Danone has told outsiders that it is unlikley to win the unit, but that Pfizer is trying to keep them in the auction, one of the people said. Bloomberg said a third bidder is no longer in the running.

Separately, Pfizer has hired JPMorgan Chase & Co, Bank of America Merrill Lynch and Morgan Stanley for a potential initial public offering of its animal health business, a source familiar with the situation said.

Pfizer put its infant nutrition and animal health businesses up for sale last July as it looks to focus on its core pharmaceuticals business.

A company official said on Tuesday that no decisions have been made and that Pfizer will be in a position to announce any decisions this year. The company expects to complete any transactions between July of this year and July 2013.

Regarding the animal health business, the official said a spin-off was most likely.

A Nestle spokesman was not immediately available for comment.

A person familiar with the negotiations said a deal for the infant nutrition unit was expected "in the near future," but not this week.

Pfizer's infant nutrition business sells baby formula and maternal supplements. It generates over 70 percent of its $2.1 billion in sales in emerging markets, with over a quarter coming from China, where the $6 billion market is expected to double by 2016.

The Pfizer business competes with products from Nestle and Danone, as well as Mead Johnson's Enfamil and Abbott Laboratories' Similac.

Pfizer shares closed 1.5 percent higher on Tuesday.

(Reporting by Olivia Oran, Ransdell Pierson, Martinne Geller and Michael Erman in New York; Editing by Gunna Dickson, Bernard Orr, Tim Dobbyn and Sugita Katyal)

FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared
People walk in the Wipro campus in Bangalore June 23, 2009. REUTERS/Punit Paranjpe/Files

Wipro Q4 net profit beats estimates, rises 29 percent

Wipro posted a 29 percent rise in its fourth-quarter net profit, beating expectations, helped by increased IT spending by its customers. For the quarter ended March 31, the company said it earned 22.27 billion rupees compared with 17.29 billion rupees a year earlier.  Full Article | Full Coverage 

REUTERS SHOWCASE

Election 2014

Election 2014

India holds biggest day of voting with BJP gaining strength  Read | Full Coverage 

Market Eye

Market Eye

Sensex jumps 351 points, snaps 3-day losing streak  Full Article 

Insider Trading Case

Insider Trading Case

Ex-Goldman director Rajat Gupta to surrender June 17 in insider case.  Full Article 

Expansion Plans

Expansion Plans

Reliance Industries, HPCL Mittal plan refinery expansions.  Full Article 

S&P on India

S&P on India

S&P: India's ratings to depend on next govt econ, fiscal policies.  Full Article 

Ambitious Aim

Ambitious Aim

In green car race, Toyota adds muscle with fuel-cell launch.  Full Article 

Deal Talk

Deal Talk

Piramal to buy 20 percent stake in Shriram Capital for $334 million.  Full Article 

Bond Market

Bond Market

A star abroad, RBI boss riles bond traders at home  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device.  Full Coverage